Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27451514 | 1.00 | DDB1 (0.55) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL30193041 | 0.85 | DDB1 (0.56) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL31444083 | 0.84 | DDB1 (0.56) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL27089927 | 0.83 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL30631086 | 0.83 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL26633418 | 0.83 | DDB1 (0.59) | DDB1CRBNNAMPTPDK4CDK7 | |
| SCHEMBL30257373 | 0.82 | DDB1 (0.62) | DDB1CRBN | |
| SCHEMBL23538658 | 0.81 | DDB1 (0.69) | DDB1CRBNNAMPT | |
| SCHEMBL21965415 | 0.81 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL30796982 | 0.81 | DDB1 (0.51) | DDB1CRBNNAMPTPDK4CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |